Surrozen, Inc./DE Foreign Currency Transaction Gain (Loss), before Tax
Surrozen, Inc./DE (SRZN) reported Foreign Currency Transaction Gain (Loss), before Tax of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-06
- Surrozen, Inc./DE foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$278.00K.
- Surrozen, Inc./DE foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE foreign currency transaction gain (loss), before tax for fiscal 2025 was $0.00.
- Surrozen, Inc./DE foreign currency transaction gain (loss), before tax for fiscal 2024 was -$113.00K, a 164.94% decline from fiscal 2023.
- Surrozen, Inc./DE foreign currency transaction gain (loss), before tax for fiscal 2023 was $174.00K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | -$278.00K derived: sum of 3 quarters · filed 2026-08-06 | -$278.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | -$278.00K derived: sum of 2 quarters · filed 2026-05-06 | -$278.00K derived: sum of 3 quarters · filed 2026-05-06 | -$91.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$278.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$278.00K derived: sum of 2 quarters · filed 2026-03-23 | -$91.00K derived: sum of 3 quarters · filed 2026-08-06 | $0.00 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $187.00K derived: sum of 2 quarters · filed 2026-08-06 | $278.00K 10-Q · filed 2025-11-07 | $121.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $187.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $278.00K 10-Q · filed 2026-08-06 | $121.00K derived: sum of 3 quarters · filed 2026-08-06 | $205.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $91.00K 10-Q · filed 2026-05-06 | -$66.00K derived: sum of 2 quarters · filed 2026-05-06 | $18.00K derived: sum of 3 quarters · filed 2026-05-06 | $2.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$73.00K derived: sum of 2 quarters · filed 2026-03-23 | -$89.00K derived: sum of 3 quarters · filed 2026-03-23 | -$113.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $68.00K derived: sum of 2 quarters · filed 2025-11-07 | $44.00K 10-Q · filed 2025-11-07 | $218.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$40.00K 10-Q · filed 2025-08-08 | $134.00K derived: sum of 3 quarters · filed 2025-08-08 | $134.00K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$24.00K 10-Q · filed 2025-05-09 | $150.00K derived: sum of 2 quarters · filed 2025-05-09 | $150.00K derived: sum of 3 quarters · filed 2025-05-09 | $150.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $174.00K derived: sum of 2 quarters · filed 2025-03-31 | $174.00K derived: sum of 3 quarters · filed 2025-03-31 | $174.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |